We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Comparison of Antibiotics for Pseudomonas in Early CF (CAPEC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00823238
Recruitment Status : Completed
First Posted : January 15, 2009
Last Update Posted : April 18, 2011
Cystic Fibrosis Foundation Therapeutics
Information provided by:
University of North Carolina, Chapel Hill

Brief Summary:
This is a prospective, randomized clinical trial comparing the effects of these 2 modes of antibiotic treatment on BALF inflammation in young, P. aeruginosa-positive CF patients.

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: ceftazidime and tobramycin Drug: inhaled tobramycin Phase 1

Detailed Description:
Cystic fibrosis (CF) is a genetic disorder which is typically fatal during early adulthood, due to progressive bronchiectasis and respiratory failure. Chronic lung infection with Pseudomonas aeruginosa begins in early life and is clearly associated with decline (especially mucoid phenotypes), making this infection a major target of therapy. The inflammatory response to infection may also be dysregulated in CF, so that suppression of airway inflammation is a second major goal of therapy. However, "best practice" for treatment of Pseudomonas infection in early CF is not defined (several recently published commentaries available upon request) and is a critical issue currently in clinical management of CF. Inhaled tobramycin alone has been reported to be effective at short-term eradication of P. aeruginosa from bronchoalveolar lavage fluid (BALF) in children with cystic fibrosis (CF) age 3 mo-6 yr, but inflammation was unaffected by this treatment, and recurrence of infection occurred fairly quickly for mucoid strains. The ideal treatment would result in long-term reduction in both bacterial quantity and inflammation. Some bacteria in the CF airway may be both inaccessible to inhaled antibiotics, and "hidden" from BALF, by location in inspissated secretions, and P. aeruginosa may not be effectively eradicated in paranasal sinuses. Thus, it is reasonable to hypothesize that treatment with parenteral antibiotics provides better overall eradication of organisms and consequently reduced stimulus for ongoing or recurrent inflammation in the airways. We therefore propose a prospective, randomized clinical trial comparing the effects of these 2 modes of antibiotic treatment on BALF inflammation in young, P. aeruginosa-positive CF patients.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Antibiotics for Pseudomonas in Early CF
Study Start Date : July 2004
Primary Completion Date : May 2008
Study Completion Date : May 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Tobramycin
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: systemic Drug: ceftazidime and tobramycin
Active Comparator: inhaled Drug: inhaled tobramycin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   3 Months to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Positive respiratory culture (sputum, BALF, or deep pharyngeal culture) in the past 3 months for P. aeruginosa. Those who are culture positive for both P. aeruginosa and additional bacteria (S. aureus, H. influenzae) would also be eligible (but see microbiologic exclusions below). Children with either first isolate or chronic/repeated P. aeruginosa infection are eligible.
  2. Clinically stable as defined by:

    1. No systemic anti-P. aeruginosa antibiotics in the past 2 mo, and no TOBI in the past 1 month;
    2. No pulmonary exacerbation in the past 1 mo (definition furnished on request); and
    3. FEV1 ≥ 70% predicted (best baseline past 6 months and at study entry) for those old enough to reliably test spirometric lung function.

Exclusion Criteria:

  1. Recent (within past 2 mo) use of systemic anti-Pseudomonas antibiotics, with the exception of chronic (three times a week) azithromycin;
  2. Recent (within past 2 wk) use of systemic anti-inflammatory agents;
  3. Mycobacterial pathogens on AFB smear at initial bronchoscopy;
  4. Multiple-drug resistant (MDR)-P. aeruginosa, or oxacillin-resistant S. aureus (ORSA) on respiratory cultures in the past 3 months. If either MDR-P. aeruginosa, or ORSA are isolated at the initial bronchoscopy, subjects will be excluded and results discussed with primary caregiver.
  5. Viral pathogens are occasionally isolated from BALF but this may take 2-3 weeks. Thus, any subjects with this result after initial bronchoscopy will likely have completed the treatment protocol, but would not undergo bronchoscopy #2.
  6. History of reactions to or problems with anesthesia or sedation.
  7. History of reactions to or problems with aminoglycosides (medicines like tobramycin or gentamicin).
  8. History of hemoptysis (coughing up blood) within 30 days prior to entry.
  9. History of anemia or thrombocytopenia.
  10. Administration of any investigational drug within 30 days prior to entry.
  11. History of abnormal kidney function (greater than 1.5 times the upper limit of normal serum creatinine for age).
  12. History of documented chronic hearing loss.
  13. for children under the age of 3 months, prematurity defined as gestational age < 36 weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00823238

Sponsors and Collaborators
University of North Carolina, Chapel Hill
Cystic Fibrosis Foundation Therapeutics
Principal Investigator: Terry Noah, MD UNC-CH

Responsible Party: Terry L. Noah, MD, UNC Chapel Hill
ClinicalTrials.gov Identifier: NCT00823238     History of Changes
Other Study ID Numbers: GCRC2197
First Posted: January 15, 2009    Key Record Dates
Last Update Posted: April 18, 2011
Last Verified: April 2011

Additional relevant MeSH terms:
Cystic Fibrosis
Pseudomonas Infections
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Gram-Negative Bacterial Infections
Bacterial Infections
Anti-Bacterial Agents
Anti-Infective Agents